GNTA
- Genenta Science S.p.A.
()
Overview
Company Summary
Genenta Science S.p.A. is a biotechnology company that specializes in developing gene therapies for the treatment of cancer and other genetic diseases. The company utilizes a unique technology known as Hematopoietic Stem Cell Gene Therapy (HSC-GT) to modify patients' own hematopoietic stem cells and reinfuse them back into the body.
Genenta Science's approach involves using a viral vector to deliver therapeutic genes into the patient's stem cells, thereby enabling targeted and sustained production of therapeutic proteins. This innovative strategy aims to address the limitations of traditional cancer treatments by directly attacking tumors and boosting the immune system while minimizing potential side effects.
The company focuses on different types of cancer, including multiple myeloma and acute myeloid leukemia, which are aggressive and difficult-to-treat malignancies. By precisely targeting cancer cells and reducing the risk of relapse, Genenta Science aims to improve patient outcomes and ultimately provide a potential cure for these diseases.
Apart from treating cancer, Genenta Science is also exploring the application of its gene therapy technology for other genetic disorders such as rare genetic immunodeficiencies, where the correction of genetic defects in hematopoietic stem cells could offer significant therapeutic benefits.
Through its scientific expertise and ongoing research and development efforts, Genenta Science strives to advance the field of gene therapy and bring innovative treatments to patients in need, aiming to make a positive impact on the lives of those affected by cancer and genetic diseases.